The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 11, 2018

Filed:

Oct. 29, 2013
Applicant:

Arizona Board of Regents on Behalf of University of Arizona, Tucson, AZ (US);

Inventors:

Eugene Gerner, Tucson, AZ (US);

Edwin Paz, Tucson, AZ (US);

Bonnie Lafleur, Tucson, AZ (US);

Jenaro Garcia-Huidobro, Tucson, AZ (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/198 (2006.01); A61K 45/06 (2006.01); A61K 31/192 (2006.01); G01N 33/574 (2006.01); C12Q 1/6886 (2018.01); C12Q 1/18 (2006.01); A61K 31/196 (2006.01); A61K 31/616 (2006.01); A61K 31/635 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57496 (2013.01); A61K 31/192 (2013.01); A61K 31/196 (2013.01); A61K 31/198 (2013.01); A61K 31/616 (2013.01); A61K 31/635 (2013.01); A61K 45/06 (2013.01); C12Q 1/18 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57492 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01); G01N 2333/4703 (2013.01); G01N 2800/52 (2013.01);
Abstract

The present disclosure relates to therapeutic methods and medical uses comprising the identification and use of cancer marker surrogates for increased polyamine expression. These markers may be used to identify patients who may be treated for diseases and disorders that are susceptible to polyamine synthesis inhibitors, and they can also be used to monitor therapeutic responses when such agents are used. More specifically, reduced levels of let-7 miRNA and elevated levels of LIN28 and HMGA2 proteins were found to correlate with elevated levels of polyamines and may be used for predicting the efficacy of cancer therapy using an ornithine decarboxylase (ODC1) inhibitor such as eflornithine (DFMO), suitably in combination with an NSAID such as sulindac.


Find Patent Forward Citations

Loading…